SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Laurus Labs inches up on the bourses

17 Jan 2018 Evaluate

Laurus Labs is currently trading at Rs. 545.40, up by 11.65 points or 2.18% from its previous closing of Rs. 533.75 on the BSE.

The scrip opened at Rs. 550.00 and has touched a high and low of Rs. 556.95 and Rs. 541.30 respectively. So far 33257 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 634.00 on 12-Jun-2017 and a 52 week low of Rs. 468.00 on 03-Feb-2017.

Last one week high and low of the scrip stood at Rs. 556.95 and Rs. 531.15 respectively. The current market cap of the company is Rs. 5778.62 crore.

The promoters holding in the company stood at 30.57%, while Institutions and Non-Institutions held 50.60% and 18.83% respectively.

Laurus Labs has been certified as the ‘Great Place to Work For’, in the large sized organizations category in India, in the 2018 edition of Great Place to Work- a study by Great Place To Work Institute.

Every year, more than 8000 organizations from over 50 countries partner Great Place to Work Institute for assessment, benchmarking and planning actions to assess and strengthen their workplace culture. It is an important step for the organization in its journey to build a High-Trust, High-Performance Culture and Laurus Labs organization has successfully accomplished this milestone.

The Institute assesses workplace culture through 2 primary lenses to evaluate and identify the best cultures. The first lens measures the quality of employee experience through the globally validated survey instrument known as Trust Index.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs Share Price

1113.50 -15.30 (-1.36%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×